Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and diabetes treatment ... and regulate their blood sugar.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback